Nascent Biotech, Inc. (NBIO)
Develops antibody drugs to treat brain cancer and other solid tumors.
$0.00+0.00%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-70.0%
The outlook
NBIO is trading at the extreme low end of its 52-week range, well below both short- and long-term moving averages. Analyst coverage appears minimal or absent. The overall sentiment snapshot reflects a bearish lean based on current price positioning and technical levels.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
$103,330
52-wk high
$0.13
52-wk low
$0.00
50-day avg
$0.00
200-day avg
$0.00
Trailing P/E
—